Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News ESC 2018

MATRIX: 1-Year Results Confirm Superiority of Transradial PCI

Michael O'Riordan

August 25, 2018

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

News Daily News

Cancelled Cath Lab Activations and Timely Reperfusion: A ‘Balancing Act’

Michael O'Riordan

August 21, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

High-Sensitivity Troponin T Safely Rules Out More MI Patients, and Faster, Than Conventional Assay

Michael O'Riordan

August 14, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

Advertisement

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

MATRIX: 1-Year Results Confirm Superiority of Transradial PCI

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Cancelled Cath Lab Activations and Timely Reperfusion: A ‘Balancing Act’

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

High-Sensitivity Troponin T Safely Rules Out More MI Patients, and Faster, Than Conventional Assay

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

New Review Probes Possibility of CVD Prevention Without Aspirin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content